Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613921 · ClinicalTrials.gov registry record
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
A clinical trial of Liver Diseases and Liver Cirrhosis, sponsored by European Foundation for Study of Chronic Liver Failure.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 20
- Study locations
NCT04613921 is a study of Liver Diseases and Liver Cirrhosis that is actively recruiting participants, run by European Foundation for Study of Chronic Liver Failure. The registered enrollment target is 3,000 participants, below the 61,068-participant average among 33 other Liver Diseases trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04613921, a study of Liver Diseases and Liver Cirrhosis, is actively recruiting participants, sponsored by European Foundation for Study of Chronic Liver Failure.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.
Conditions Studied
Interventions
- OTHER Observational Protocol
Study Locations (20)
New York
- Weill Cornell Medicine - New York
- Icahn School of Medicine at Mount Sinai - New York
- Montefiore Medical Center - New York
Texas
- Baylor College of Medicine (Scott & White) - Dallas
- Michael E DeBakey VA Medical Center - Houston
- Baylor St. Luke's Medical Centre - Houston
Illinois
- Northwestern Memorial Hospital - Chicago
- The University of Chicago Medicine - Chicago
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic - Cleveland
Other
- Austral University Hospital - Buenos Aires
- Hospital Alemán - Buenos Aires
California
- Cedars-Sinai Comprehensive Transplant Center - Los Angeles
Colorado
- University of Colorado - Aurora
Florida
- Tampa General Hospital - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04613921
The ClinicalTrials.gov registry entry for NCT04613921 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61,068-participant average among 33 other Liver Diseases trials with a reported enrollment target (95% lower). The listed sponsor is European Foundation for Study of Chronic Liver Failure, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention - of which Observational Protocol is the first listed.
NCT04613921 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT04613921 about?
NCT04613921 is a clinical study titled "Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs". Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to ma...
What is the current status of trial NCT04613921?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2021-07-08. Estimated completion is 2026-12-31.
What conditions does trial NCT04613921 study?
This clinical trial studies the following conditions: Liver Diseases, Liver Cirrhosis, Liver Transplant, Complications, Acute-On-Chronic Liver Failure.
What interventions are being tested in trial NCT04613921?
The interventions under investigation include: Observational Protocol (OTHER).
Who is sponsoring clinical trial NCT04613921?
This trial is sponsored by European Foundation for Study of Chronic Liver Failure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04613921 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Genetic Collection Protocol
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.